Dr George Lee returns to discuss the latest medical news. Expect deep insights delivered with generous humour. Earlier this week, the Health Ministry announced that it has approved the biosimilar version of trastuzumab, a targeted therapy for women with HER2-positive breast cancer. The biosimilar version will significantly reduce the cost of treatment, which currently costs RM130,000 a year. Datin Paduka Prof Dr Teo Soo Hwang, CEO of Cancer Research Malaysia, joins us to discuss how biosimilar therapies can improve accessibility to cancer care.

Your browser does not support native audio, but you can download this MP3 to listen on your device.

Leave a Reply